The Effect of Triptorelin on Electrocardiogram

Evaluation of Changes in Electrocardiogram's Intervals During Treatment with Gonadotropin-Releasing Hormone Agonists in Patients with precocious puberty

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190314043051N1

Enrollment

Registered

2019-03-18

Start date

2019-03-20

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

precocious puberty. Precocious puberty

Interventions

Triptorelin (FERRING, Germany) as a gonadotropin-releasing hormone agonist in the form of 0.1 mg ampule will be administered as the intramuscular injection once a month to children with precocious pub

Eligibility

Sex/Gender

All

Age

2 Years to 9 Years

Inclusion criteria

Inclusion criteria: Children with precocious puberty Referring to Endocrinology Clinic of Tabriz Children Hospital

Exclusion criteria

Exclusion criteria: Having any type of previous cardiac disease

Design outcomes

Primary

Measure	Time frame
QRS interval duration in electrocardiogram. Timepoint: Before the intervention and 6, 12, and 18 weeks after the starting of gonadotropin releasing hormone agonists. Method of measurement: Electrocardiography.;PR interval duration in electrocardiogram. Timepoint: Before the intervention and 6, 12, and 18 weeks after the starting of gonadotropin releasing hormone agonists. Method of measurement: Electrocardiography.;QT interval duration in electrocardiogram. Timepoint: Before the intervention and 6, 12, and 18 weeks after the starting of gonadotropin releasing hormone agonists. Method of measurement: Electrocardiography.	—

Measure

Time frame

QRS interval duration in electrocardiogram. Timepoint: Before the intervention and 6, 12, and 18 weeks after the starting of gonadotropin releasing hormone agonists. Method of measurement: Electrocardiography.;PR interval duration in electrocardiogram. Timepoint: Before the intervention and 6, 12, and 18 weeks after the starting of gonadotropin releasing hormone agonists. Method of measurement: Electrocardiography.;QT interval duration in electrocardiogram. Timepoint: Before the intervention and 6, 12, and 18 weeks after the starting of gonadotropin releasing hormone agonists. Method of measurement: Electrocardiography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSiamak Shiva

Tabriz University of Medical Sciences

shivasiamak@yahoo.com+98 41 3526 2265

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026